Exelixis files patent suit against India's Cipla over Cabometyx generics [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
The lawsuit filed in a Delaware district court on Thursday follows Cipla's move to amend its previously filed marketing application, targeted at FDA authorization for additional doses of its Cabometyx version. With its lawsuit, the Alameda, California-based cancer drugmaker seeks a court order to prevent Cipla from receiving FDA authorization for its Cabometyx versions before the expiry of relevant patents. Exelixis ( EXEL ) first filed a lawsuit against Mumbai-based Cipla in March 2023 after the generic drugmaker submitted its original Abbreviated New Drug Application for its Cabometyx generic early last year. Cabometyx, a tyrosine kinase inhibitor indicated in the U.S. for liver and kidney cancer, added $1.6B in net product revenue for Exelixis ( EXEL ) in 2023, with ~17% YoY growth. Recommended For You More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Stephens from $23.00 to $29.00. They now have an "equal weight" rating on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Guggenheim from $32.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Piper Sandler from $33.00 to $36.00. They now have an "overweight" rating on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $34.00 price target on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Wells Fargo & Company from $32.00 to $36.00. They now have an "overweight" rating on the stock.MarketBeat
EXEL
Earnings
- 10/29/24 - Beat
EXEL
Sec Filings
- 10/30/24 - Form 4
- 10/30/24 - Form 144
- 10/29/24 - Form 10-Q
- EXEL's page on the SEC website